## IQV: IQVIA Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($215.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Understanding Momentum Shifts in (IQV)**
- Source: Stock Traders Daily | 20251221T075600 | Neutral | Relevance: 100%
- Iqvia Holdings Inc. (NYSE: IQV) is exhibiting a neutral sentiment across all horizons, suggesting a sideways action. AI models have generated three distinct trading strategies for different risk profiles: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy. The stock shows a mid-channel oscillation pattern, with an exceptional 46.2:1 risk-reward short setup.

**2. IQVIA’s Debt Refinancing Could Be A Game Changer For IQVIA Holdings (IQV)**
- Source: Simply Wall Street | 20251223T050901 | Somewhat-Bullish | Relevance: 100%
- IQVIA Holdings (IQV) recently refinanced its credit agreement, reducing interest on some US dollar borrowings and optimizing its capital structure. This move aims to enhance financial flexibility and support investments in AI, data, and clinical research, addressing near-term risks related to leverage and interest costs. While the refinancing improves financial headroom, the company's investment narrative still hinges on its ability to convert its R&D backlog and AI initiatives into resilient earnings amidst margin pressures and high debt levels.

**3. IQVIA’s Debt Refinancing Could Be A Game Changer For IQVIA Holdings (IQV)**
- Source: Simply Wall Street | 20251223T044557 | Somewhat-Bullish | Relevance: 100%
- IQVIA Holdings Inc. recently refinanced its debt, including term and revolving loan facilities, and reduced interest on some US dollar borrowings. This move aims to optimize the company's capital structure and cut interest costs, potentially enhancing financial flexibility for its AI, data, and clinical research initiatives. While it eases near-term leverage risks, the core investment narrative remains IQVIA's ability to convert its R&D backlog and AI efforts into resilient earnings amidst competitive pressures.

**4. SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA**
- Source: The Globe and Mail | 20251223T070912 | Neutral | Relevance: 64%
- SCIENTURE HOLDINGS, INC. has provided an update on the commercial launch of REZENOPY® (naloxone HCl) Nasal Spray 10 mg, an FDA-approved high-strength opioid overdose treatment. The company expects the product to be ready for wholesale channel loading in Q1 2026, with commercial availability beginning in early Q2 2026, addressing a critical unmet need in emergency overdose response. REZENOPY® is designed to be more effective against potent opioids and for patients requiring multiple doses of lower-strength naloxone.

**5. Backbone of Discovery: A Deep Dive into Charles River Laboratories (CRL)**
- Source: FinancialContent | 20251223T101000 | Neutral | Relevance: 64%
- Charles River Laboratories (CRL) is an indispensable backbone of the global pharmaceutical industry, participating in the development of over 80% of FDA-approved drugs in the last five years. After a tumultuous period, CRL is undergoing a strategic realignment with a $1 billion buyback program and a pivot towards AI-driven discovery, aiming to evolve into a high-tech drug development powerhouse. The company's business model spans Discovery and Safety Assessment, Research Models and Services, and Manufacturing Solutions, with its stock recovering in 2025 due to regulatory resolutions and a focus on shareholder returns.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 2 ($4.59M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $4.6M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($4.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.3B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 17.4 |
| Current P/E | 18.9 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.1% to -0.4% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.4pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.54), momentum weakening. RSI neutral at 55. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.36% (CS: 63) | Neutral |
| RSI_14 | 55.3 | Neutral |
| MACD Histogram | -0.54 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.027x | Above |
| vs SMA200 | 1.233x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $225.17
- **Stop Loss:** $215.09 (4.5% risk)
- **Target:** $235.25 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 119
- **Position Value:** $26,795.23
- **Portfolio %:** 26.80%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*